PMID- 35045614
OWN - NLM
STAT- MEDLINE
DCOM- 20220121
LR  - 20220121
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 50
IP  - 1
DP  - 2022 Jan 24
TI  - [Efficacy and safety of percutaneous transluminal pulmonary angioplasty in 
      patients with chronic thromboembolic pulmonary hypertension].
PG  - 49-54
LID - 10.3760/cma.j.cn112148-20211202-01040 [doi]
AB  - Objective: To explore the efficacy and safety of percutaneous transluminal 
      pulmonary angioplasty (PTPA) in patients with chronic thromboembolic pulmonary 
      hypertension (CTEPH). Methods: This prospective single arm study included 19 
      CTEPH patients (7 male, age(56.3+/-12.5)years) admitted to Wuhan Asia Heart 
      Hospital from January 2017 to June 2019 and received PTPA interventional therapy. 
      Baseline data, including age, sex, WHO functional class, 6-minute walk distance 
      (6MWD), NT-proBNP, right heart catheterization values, were collected. Patients 
      received single or repeated PTPA. Number of dilated vessels from each patient was 
      analyzed, patients were followed up for 24 weeks and right heart catheterization 
      was repeated at 24 weeks post initial PTPA. All-cause death, perioperative 
      complications, and reperfusion pulmonary edema were reported. WHO functional 
      class, 6MWD, NT-proBNP, right heart catheterization values were compared between 
      baseline and at 24 weeks follow up. Results: Nineteen CTEPH patients received a 
      total of 56 PTPA treatments. The pulmonary artery pressure (mPAP) decreased from 
      (40.11+/-7.55) mmHg (1 mmHg=0.133 kPa) to (27.53+/-4.75) mmHg (P<0.001), and the 
      total pulmonary resistance (TPR) decreased from (13.00+/-3.56) Wood U to 
      (5.48+/-1.56) Wood U (P<0.001), cardiac output increased from (3.19+/-0.63) L/min to 
      (5.23+/-0.94) L/minutes (P<0.01) at 24 weeks post PTPA. The WHO functional class 
      improved significantly (P<0.001), 6MWD increased from (307.08+/-129.51) m to 
      (428.00+/-112.64) m (P=0.002), the NT-proBNP decreased at 24 weeks post PTPA 
      (P=0.002). During the follow-up period, there was no death; hemoptysis occurred 
      in 4 patients during the operation, none of which resulted in serious adverse 
      clinical consequences. One patient developed reperfusion pulmonary edema and 
      recovered after treatment. Conclusion: PTPA treatment is safe and can 
      significantly improve the hemodynamics and WHO functional class of patients with 
      CTEPH.
FAU - Jin, B W
AU  - Jin BW
AD  - Department of Cardiovascular Surgery, Wuhan Asia Heart Hospital, Wuhan 430000, 
      China.
FAU - Zhang, G C
AU  - Zhang GC
AD  - Department of Cardiovascular Surgery, Wuhan Asia Heart Hospital, Wuhan 430000, 
      China.
FAU - Shen, Q S
AU  - Shen QS
AD  - Department of Cardiovascular Surgery, Wuhan Asia Heart Hospital, Wuhan 430000, 
      China.
FAU - Long, K
AU  - Long K
AD  - Department of Cardiovascular Surgery, Wuhan Asia Heart Hospital, Wuhan 430000, 
      China.
LA  - chi
GR  - WX17D44/Scientific Research Fund of Wuhan Health Committee/
PT  - Journal Article
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angioplasty
MH  - *Angioplasty, Balloon
MH  - Chronic Disease
MH  - Humans
MH  - *Hypertension, Pulmonary/surgery
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pulmonary Artery/surgery
MH  - *Pulmonary Embolism
MH  - Treatment Outcome
EDAT- 2022/01/21 06:00
MHDA- 2022/01/22 06:00
CRDT- 2022/01/20 01:22
PHST- 2022/01/20 01:22 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/01/22 06:00 [medline]
AID - 10.3760/cma.j.cn112148-20211202-01040 [doi]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2022 Jan 24;50(1):49-54. doi: 
      10.3760/cma.j.cn112148-20211202-01040.